<html>

  <head>
    <title>oncolinform8k31408.htm</title>
<!-- Licensed to: SCJ Resources Corporation-->
<!-- Document Created using EDGARizer 4.0.3.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
      STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
      D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM
      8-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
      REPORT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      of
      report (Date of earliest event reported):&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">March
      14,
      2008</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none"><font style="FONT-SIZE: 13pt; FONT-FAMILY: Times New Roman">Oncolin
      Therapeutics,
      Inc.</font></font></font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: none">(Exact
      Name of Registrant as Specified in Its Charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none">Nevada
</font></font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: none">(State
      or Other Jurisdiction of Incorporation)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="middle" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">000-50541</font></font>
                <hr style="COLOR: black" align="left" noshade size="1" width="100%">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="middle" width="37%">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">88-0507007</font></font>
                <hr style="COLOR: black" align="left" noshade size="1" width="100%">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S.
                Employer Identification No.)</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" width="37%">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1330
                Post Oak Blvd., Suite
                1600</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Houston,
                Texas 77056</font></font>
                <hr style="COLOR: black" align="left" noshade size="1" width="100%">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Address
                of Principal Executive Offices)</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
            <td valign="bottom" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">77056</font></font>
                <hr style="COLOR: black" align="left" noshade size="1" width="100%">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Zip
                Code)</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-SIZE: 13pt"><font style="FONT-WEIGHT: bold; FONT-SIZE: 13pt; FONT-FAMILY: times new roman">Edgeline
      Holdings, Inc.</font></font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      name or former address, if changed since last report)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s
      telephone number, including area code:&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">(713)
      621-5208</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions (see General Instruction A.2. below):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="5%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">[&#160;&#160;&#160;]</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
            <td align="left" valign="top" width="68%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="5%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">[&#160;&#160;&#160;]</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
            <td align="left" valign="top" width="68%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="5%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">[&#160;&#160;&#160;]</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
            <td align="left" valign="top" width="68%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b))</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="5%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">[&#160;&#160;&#160;]</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
            <td align="left" valign="top" width="68%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c))</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      1.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Entry into a Material Definitive Agreement.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On
      March 14, 2008, Edgeline Holdings,
      Inc. (the &#8220;Company&#8221;) entered into a stock purchase agreement (&#8220;SPA&#8221;) with
      Intertech Bio Corporation (&#8220;Intertech Bio&#8221;) and J. Leonard Ivins (&#8220;Ivins&#8221;),
      whereby the Company acquired 25,000 shares of Intertech Bio from Ivins in
      exchange for the issuance of 1,600,000 shares of the Company&#8217;s common stock
      (&#8220;Company Shares&#8221;).&#160;&#160;In connection with the SPA, the Company and Ivins
      entered into a lock-up/leak-out agreement, which prohibits the sale of the
      Company Shares for a period of 18 months from the date of the SPA and thereafter
      limits the sale of the Company Shares for an additional period of 18 months<font style="DISPLAY: inline; COLOR: #000000">.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 72pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
                5.02</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Departure
                of Directors or Principal Officers; Election of Directors; Appointment
                of
                Principal Officers </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">On
      March 1</font><font style="DISPLAY: inline; COLOR: #000000">4</font><font style="DISPLAY: inline; COLOR: #000000">,
      2008, Mr. Carl A. Chase </font><font style="DISPLAY: inline; COLOR: #000000">(&#8220;Chase&#8221;) </font><font style="DISPLAY: inline; COLOR: #000000">resigned
      as a director from the Company
      and as the Company&#8217;s chief financial officer</font><font style="DISPLAY: inline; COLOR: #000000">.&#160;&#160;Both resignations are
      </font><font style="DISPLAY: inline; COLOR: #000000">effective </font><font style="DISPLAY: inline; COLOR: #000000">immediately</font><font style="DISPLAY: inline; COLOR: #000000">.</font><font style="DISPLAY: inline; COLOR: #000000">&#160;&#160;In
      May 2007, Chase and the
      Company entered into an employment agreement (&#8220;Employment Agreement&#8221;), which was
      terminated upon Chase&#8217;s resignation.&#160;&#160;In connection with terminating
      the Employment Agreement, the Company agreed to pay Chase and his affiliate
      a
      $15,000 consulting fee in lieu of accrued salary payments under the Employment
      Agreement.&#160;&#160;In order to settle additional outstanding amounts owed to
      Chase and his affiliate, the Company agreed to pay approximately $44,350, of
      which (i) $14,951, plus all additional accrued interest, is due and payable
      on
      May 15, 2008 and (ii) $29,399, plus all additional accrued interest, is due
      and
      payable on June 1, 2008.&#160;&#160;Chase was issued 1,600,000 shares of the
      Company&#8217;s common stock (&#8220;Shares&#8221;) pursuant to the Employment Agreement, all of
      which were subject to a lock-up/leak-out agreement (&#8220;LL Agreement&#8221;) and a
      buy-back agreement (&#8220;BB Agreement&#8221;).&#160;&#160;Upon termination of the
      Employment Agreement, all of the Shares remain subject to the LL Agreement,
      542,076 of the Shares are no longer subject to the BB Agreement and the
      remaining 1,057,924 Shares remain subject to the BB until June 30,
      2008.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">On
      March 14, 2008, </font><font style="DISPLAY: inline; COLOR: #000000">Mr. Steven M. Plumb</font><font style="DISPLAY: inline; COLOR: #000000">,
      age 48,</font><font style="DISPLAY: inline; COLOR: #000000">was appointed to serve
      as the Company&#8217;s
      chief financial officer </font><font style="DISPLAY: inline; COLOR: #000000">(&#8220;CFO&#8221;) </font><font style="DISPLAY: inline; COLOR: #000000">as
      a result of Mr. Chase&#8217;s
      resignation.&#160;&#160;</font>Mr. Plumb is a CPA licensed to practice in Texas.
      Mr. Plumb is a financial manager and senior executive experienced in operations,
      finance and marketing. Mr. Plumb is the president of Clear Financial Solutions,
      Inc. a business consulting firm that assists public and private companies with
      financing, operations improvement, outsourced accounting, SEC reporting, mergers
      and acquisitions, and financial analysis. From 2002 through 2004, Mr. Plumb
      served as Vice President and Chief Financial Officer of Adventrx
      Pharmaceuticals, Inc. Prior to this, Mr. Plumb served as the Chief Financial
      Officer of DePelchin Children's Center, and as controller of Memorial City
      Rehabilitation Hospital in Houston, Texas.&#160; Mr. Plumb is a former auditor
      and consultant with KPMG. Mr. Plumb earned his BBA degree in accounting from
      the
      University of Texas at Austin.&#160;&#160;In connection with his appointment,
      the Company and Mr. Plumb entered into an agreement pursuant to which Mr. Plumb
      will be compensated approximately $2,400 per month.&#160;&#160;Mr. Plumb will
      also be entitled to receive the following options to purchase shares of the
      Company&#8217;s common stock (&#8220;Shares&#8221;) under the Company&#8217;s 2007 Stock Option Plan:
      (i) an option to purchase 50,000 Shares at a purchase price of $0.10 per Share,
      with 25,000 Shares vesting upon execution of the agreement (&#8220;Execution&#8221;) and
      25,000 Shares vesting one year from the date of Execution; (ii) an option to
      purchase 50,000 Shares at a purchase price of $0.25 per Share vesting two years
      from the date of Execution; and (i) an option to purchase 50,000 Shares at
      a
      purchase price of $0.25 per Share vesting three years from the date of
      Execution.&#160;&#160;The Company will reimburse Mr. Plumb for all reasonable
      business expenses incurred in performing his duties as CFO.&#160;&#160;The
      agreement contains a confidentiality clause and is for a period of one year,
      which will continue to be automatically renewed for additional one year periods
      unless cancelled by either party with 60 days written notice.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">On
      March 14, 2008, Dr. Donald Picker,
      age 62, was appointed to serve as the Company president and vice
      chairman.&#160;&#160;</font>Prior to joining the Company, Dr. Picker served as
      the President of Tapestry Pharmaceuticals, a biotech cancer company, from
      January 2007 until his employment with the Company. From April 2004 until
      January 2007, Dr. Picker served as the Executive Vice President, R&amp;D of
      Callisto Pharmaceuticals, Inc.&#160; From May 2003 until March 2004, Dr. Picker
      served as Senior Vice President, Drug Development of Callisto Pharmaceuticals,
      Inc.&#160; Dr. Picker was Chief Executive Officer and President of Synergy
      Pharmaceuticals Inc. and a member of its board of directors from September
      1999
      to April 2003.&#160; From February 1997 to September 1999, Dr. Picker was
      President and Chief Operating Officer of LXR Biotechnology Inc., an apoptosis
      drug development company.&#160; From 1991 to 1997, he was Senior Vice President
      of Research and Development at Genta Inc., an antisense drug development
      company. Dr. Picker is also a director of Xenomics, Inc., a molecular
      diagnostics company.&#160;&#160;In connection with his appointment, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr.
      Picker received a five-year option to purchase 1,900,000 shares of the Company&#8217;s
      common stock under the Company&#8217;s 2007 Stock Option Plan at a purchase price of
      $0.10 per share, which option vests in 3 equal annual installments with the
      first installment vesting one year from the date the option was
      granted.&#160;&#160;Dr. Picker previously entered into a consulting agreement
      with the Company&#8217;s subsidiary, dated November 15, 2007, whereby he agreed to
      serve as its chief technology officer.&#160;&#160;Such consulting agreement is
      for a period of six months, which may be extended at the subsidiary&#8217;s option for
      additional 3 month periods and entitles Dr Picker to (i) 300,000 shares of
      the
      Company&#8217;s common stock, (ii) $1,000 per working day, and (iii) reimbursement of
      all reasonable business expenses.&#160;&#160;The consulting agreement contains
      confidentiality and non-compete clauses and is terminable by either party upon
      30 days written notice.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Financial Statements and Exhibit</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Exhibits</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following exhibits are to be filed as part of this 8-K:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT
      NO</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">IDENTIFICATION
      OF
      EXHIBIT</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 108pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="ex991.htm">99.1</a></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="ex991.htm">Mr.
                Chase&#8217;s Letter of Resignation dated March 14, 2008
                </a></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="ex992.htm"><font style="DISPLAY: inline; COLOR: #000000">99.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <font style="DISPLAY: inline; COLOR: #000000">Agreement with Mr. Plumb dated
      March 14, 2008</font></a></font></div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="id_18" href="ex993.htm"><font style="DISPLAY: inline; COLOR: #000000">99.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <font style="DISPLAY: inline; COLOR: #000000">Agreement with Dr. Picker dated
      November 17, 2007</font></a></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="id_20" href="ex994.htm">99.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Stock Purchase Agreement dated March 14, 2008</a></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ONCOLIN
      THERAPEUTICS, INC.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 180pt"></font>By:
&#173;<font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/
      J. Leonard
      Ivins</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;J.
      Leonard Ivins, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DATE:
      March 20, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
        INDEX</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT
        NO</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">IDENTIFICATION
        OF
        EXHIBIT</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="center">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

              <tr valign="top">
                <td style="WIDTH: 108pt">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
                </td>
                <td>
                  <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
                    Chase&#8217;s Letter of Resignation dated March 14, 2008
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">99.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="DISPLAY: inline; COLOR: #000000">Agreement with Mr. Plumb
          dated
          March 14, 2008</font></font></div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="id_18"><font style="DISPLAY: inline; COLOR: #000000">99.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="DISPLAY: inline; COLOR: #000000">Agreement with Dr. Picker
          dated
          November 17, 2007</font></a></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="id_20">99.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          Stock Purchase Agreement dated March 14, 2008</a></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><a name="id_20" /></div>
    </div>
  </body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "oncolinform8k31408.htm", "description": "ONCOLIN FORM 8K 3-14-08", "secsgml_size_bytes": 37918}]
{"company-data": {"conformed-name": "Edgeline Holdings, Inc.", "cik": "0001229089", "assigned-sic": "2834", "irs-number": "880507007", "state-of-incorporation": "NV", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-50541", "film-number": "08702629"}, "business-address": {"street1": "1330 POST OAK BLVD.", "street2": "SUITE 1600", "city": "HOUSTON", "state": "TX", "zip": "77056", "phone": "713 621-5208"}, "mail-address": {"street1": "1330 POST OAK BLVD.", "street2": "SUITE 1600", "city": "HOUSTON", "state": "TX", "zip": "77056"}, "former-company": [{"former-conformed-name": "Dragon Gold Resources, Inc.", "date-changed": "20040614"}, {"former-conformed-name": "FOLIX TECHNOLOGIES INC", "date-changed": "20030425"}]}
oncolinform8k31408.htm
UNITED
      STATES
SECURITIES
      AND EXCHANGE COMMISSION
Washington,
      D.C. 20549
__________________
FORM
      8-K
CURRENT
      REPORT
Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
      of
      report (Date of earliest event reported):
March
      14,
      2008
____________________
Oncolin
      Therapeutics,
      Inc.
(Exact
      Name of Registrant as Specified in Its Charter)
Nevada
(State
      or Other Jurisdiction of Incorporation)
000-50541
(Commission
                File Number)
88-0507007
(I.R.S.
                Employer Identification No.)
1330
                Post Oak Blvd., Suite
                1600
Houston,
                Texas 77056
(Address
                of Principal Executive Offices)
77056
(Zip
                Code)
Edgeline
      Holdings, Inc.
(Former
      name or former address, if changed since last report)
Registrant's
      telephone number, including area code:
(713)
      621-5208
Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions (see General Instruction A.2. below):
[   ]
Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)
[   ]
Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)
[   ]
Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b))
[   ]
Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c))
Item
      1.01                      
Entry into a Material Definitive Agreement.
On
      March 14, 2008, Edgeline Holdings,
      Inc. (the "Company") entered into a stock purchase agreement ("SPA") with
      Intertech Bio Corporation ("Intertech Bio") and J. Leonard Ivins ("Ivins"),
      whereby the Company acquired 25,000 shares of Intertech Bio from Ivins in
      exchange for the issuance of 1,600,000 shares of the Company's common stock
      ("Company Shares").  In connection with the SPA, the Company and Ivins
      entered into a lock-up/leak-out agreement, which prohibits the sale of the
      Company Shares for a period of 18 months from the date of the SPA and thereafter
      limits the sale of the Company Shares for an additional period of 18 months
.
Item
                5.02
Departure
                of Directors or Principal Officers; Election of Directors; Appointment
                of
                Principal Officers
On
      March 1
4
,
      2008, Mr. Carl A. Chase
("Chase")
resigned
      as a director from the Company
      and as the Company's chief financial officer
.  Both resignations are
effective
immediately
.
In
      May 2007, Chase and the
      Company entered into an employment agreement ("Employment Agreement"), which was
      terminated upon Chase's resignation.  In connection with terminating
      the Employment Agreement, the Company agreed to pay Chase and his affiliate
      a
      $15,000 consulting fee in lieu of accrued salary payments under the Employment
      Agreement.  In order to settle additional outstanding amounts owed to
      Chase and his affiliate, the Company agreed to pay approximately $44,350, of
      which (i) $14,951, plus all additional accrued interest, is due and payable
      on
      May 15, 2008 and (ii) $29,399, plus all additional accrued interest, is due
      and
      payable on June 1, 2008.  Chase was issued 1,600,000 shares of the
      Company's common stock ("Shares") pursuant to the Employment Agreement, all of
      which were subject to a lock-up/leak-out agreement ("LL Agreement") and a
      buy-back agreement ("BB Agreement").  Upon termination of the
      Employment Agreement, all of the Shares remain subject to the LL Agreement,
      542,076 of the Shares are no longer subject to the BB Agreement and the
      remaining 1,057,924 Shares remain subject to the BB until June 30,
      2008.
On
      March 14, 2008,
Mr. Steven M. Plumb
,
      age 48,
was appointed to serve
      as the Company's
      chief financial officer
("CFO")
as
      a result of Mr. Chase's
      resignation.
Mr. Plumb is a CPA licensed to practice in Texas.
      Mr. Plumb is a financial manager and senior executive experienced in operations,
      finance and marketing. Mr. Plumb is the president of Clear Financial Solutions,
      Inc. a business consulting firm that assists public and private companies with
      financing, operations improvement, outsourced accounting, SEC reporting, mergers
      and acquisitions, and financial analysis. From 2002 through 2004, Mr. Plumb
      served as Vice President and Chief Financial Officer of Adventrx
      Pharmaceuticals, Inc. Prior to this, Mr. Plumb served as the Chief Financial
      Officer of DePelchin Children's Center, and as controller of Memorial City
      Rehabilitation Hospital in Houston, Texas.  Mr. Plumb is a former auditor
      and consultant with KPMG. Mr. Plumb earned his BBA degree in accounting from
      the
      University of Texas at Austin.  In connection with his appointment,
      the Company and Mr. Plumb entered into an agreement pursuant to which Mr. Plumb
      will be compensated approximately $2,400 per month.  Mr. Plumb will
      also be entitled to receive the following options to purchase shares of the
      Company's common stock ("Shares") under the Company's 2007 Stock Option Plan:
      (i) an option to purchase 50,000 Shares at a purchase price of $0.10 per Share,
      with 25,000 Shares vesting upon execution of the agreement ("Execution") and
      25,000 Shares vesting one year from the date of Execution; (ii) an option to
      purchase 50,000 Shares at a purchase price of $0.25 per Share vesting two years
      from the date of Execution; and (i) an option to purchase 50,000 Shares at
      a
      purchase price of $0.25 per Share vesting three years from the date of
      Execution.  The Company will reimburse Mr. Plumb for all reasonable
      business expenses incurred in performing his duties as CFO.  The
      agreement contains a confidentiality clause and is for a period of one year,
      which will continue to be automatically renewed for additional one year periods
      unless cancelled by either party with 60 days written notice.
On
      March 14, 2008, Dr. Donald Picker,
      age 62, was appointed to serve as the Company president and vice
      chairman.
Prior to joining the Company, Dr. Picker served as
      the President of Tapestry Pharmaceuticals, a biotech cancer company, from
      January 2007 until his employment with the Company. From April 2004 until
      January 2007, Dr. Picker served as the Executive Vice President, R&D of
      Callisto Pharmaceuticals, Inc.  From May 2003 until March 2004, Dr. Picker
      served as Senior Vice President, Drug Development of Callisto Pharmaceuticals,
      Inc.  Dr. Picker was Chief Executive Officer and President of Synergy
      Pharmaceuticals Inc. and a member of its board of directors from September
      1999
      to April 2003.  From February 1997 to September 1999, Dr. Picker was
      President and Chief Operating Officer of LXR Biotechnology Inc., an apoptosis
      drug development company.  From 1991 to 1997, he was Senior Vice President
      of Research and Development at Genta Inc., an antisense drug development
      company. Dr. Picker is also a director of Xenomics, Inc., a molecular
      diagnostics company.  In connection with his appointment,
Dr.
      Picker received a five-year option to purchase 1,900,000 shares of the Company's
      common stock under the Company's 2007 Stock Option Plan at a purchase price of
      $0.10 per share, which option vests in 3 equal annual installments with the
      first installment vesting one year from the date the option was
      granted.  Dr. Picker previously entered into a consulting agreement
      with the Company's subsidiary, dated November 15, 2007, whereby he agreed to
      serve as its chief technology officer.  Such consulting agreement is
      for a period of six months, which may be extended at the subsidiary's option for
      additional 3 month periods and entitles Dr Picker to (i) 300,000 shares of
      the
      Company's common stock, (ii) $1,000 per working day, and (iii) reimbursement of
      all reasonable business expenses.  The consulting agreement contains
      confidentiality and non-compete clauses and is terminable by either party upon
      30 days written notice.
2
Item
      9.01                      
Financial Statements and Exhibit
(d)           
      Exhibits
The
      following exhibits are to be filed as part of this 8-K:
EXHIBIT
      NO
.
IDENTIFICATION
      OF
      EXHIBIT
99.1
Mr.
                Chase's Letter of Resignation dated March 14, 2008
99.2
Agreement with Mr. Plumb dated
      March 14, 2008
99.3
Agreement with Dr. Picker dated
      November 17, 2007
99.4                                        
      Stock Purchase Agreement dated March 14, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
ONCOLIN
      THERAPEUTICS, INC.
By:
­
/s/
      J. Leonard
      Ivins
J.
      Leonard Ivins, Chief Executive Officer
DATE:
      March 20, 2008
3
EXHIBIT
        INDEX
EXHIBIT
        NO
.
IDENTIFICATION
        OF
        EXHIBIT
99.1
Mr.
                    Chase's Letter of Resignation dated March 14, 2008
99.2
Agreement with Mr. Plumb
          dated
          March 14, 2008
99.3
Agreement with Dr. Picker
          dated
          November 17, 2007
99.4                                        
          Stock Purchase Agreement dated March 14, 2008